Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Humana (HUM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Qiagen (QGEN – Research Report) and Humana (HUM – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen (QGEN)
Berenberg Bank analyst Harry Gillis maintained a Buy rating on Qiagen today and set a price target of EUR50.00. The company’s shares closed last Wednesday at $51.06.
According to TipRanks.com, Gillis is a 4-star analyst with an average return of
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $55.44, an 8.8% upside from current levels. In a report issued on January 29, TipRanks – xAI also upgraded the stock to Buy with a $61.00 price target.
See the top stocks recommended by analysts >>
Humana (HUM)
In a report released today, Kevin Fischbeck from Bank of America Securities reiterated a Hold rating on Humana, with a price target of $196.00. The company’s shares closed last Wednesday at $175.40.
According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of
Humana has an analyst consensus of Hold, with a price target consensus of $257.00, representing a 50.3% upside. In a report released today, RBC Capital also downgraded the stock to Hold with a $189.00 price target.
